According to the company tagline “Personalized Treatment Surveillance. Better Outcomes.” CareDX, Inc. is a molecular diagnostic company which is known for its AlloMap service that monitors patients with heart transplants. Current focus is on expanding the AlloMap line of blood-test products with cfDNA for Heart and cfDNA Kidney – potentially changing the lives of millions of transplant patients worldwide. Key of the company is ‘gene expression profiling,’ using the best of semiconductor industry to analyze blood cells on a molecular level, in order to identify gene activity in various types of blood cells. By building patient maps, doctors can research and predict how a patient is reacting to treatment, inflammation
Couple of months ago, we exclusively reported that the U.S. government blocked Intel from selling its products to Chinese supercomputer firms such as Inspur, responsible for building the Tianhe-2 supercomputer. Originally, Tianhe-2 was planned to expand all the way to almost 100,000 Xeon processors and Xeon Phi co-processors, targeting to beat the 100 PFLOPS barrier. Initial deployment included 4,096 Chinese Galaxy FT-1500 processors (Chinese SPARC) and 16,000 processor nodes with two 12-core Xeon E2692 processors and three Xeon Phi 31S1P co-processors for a grand total of 3.12 million cores. Full installation of Tianhe-2 was scheduled to feature 48,000 processor nodes, or 9.93 million cores. However, those
In my 30-year career as an IT hardware expert, I’ve seen thousands of roadmaps, leaked, manage-leaked and official alike. Many were on target, yet still quite a few headed for the “failed” dustbin. Among all of them, Intel’s “tick-tock” plan was probably the most ambitious one in terms of attempted consistency and predictability. Knowing the multiple interlinked uncertainties of semiconductor process, CPU architecture, ecosystem changes and others, it was a wonder in itself that it lasted for several years, until the major slippages occurred in the Sandy Bridge generation. From then on, not only there were major delays introduced to the high end lines as the
While Intel may have lost some serious income from being virtually shut out of Intel’s HPC market, the US government has recently handed the company two impressive supercomputer wins.
Just as Intel’s (NASDAQ: INTC) CEO Brian Krzanich opened the regular staff meeting before a dramatically reduced IDF2015 conference, in Shenzhen, China – it is a good time to review how government and enterprises don’t see eye to eye when it comes to strategic business. Remember the Tianhe-2 machine at Guangzhou Supercomputer Center, the current World’s number one according to Top 500 Supercomputer list? Unlike some other China supercomputers with their mixed architectures – Tianhe-2 is a fully Intel based machine, the world’s largest assembly of Intel Xeon CPUs and Xeon Phi accelerators. Even after Intel ‘opened the kimono’ and gave a nearly 70% discount on its processors and accelerators, it
Intel reported earnings of $3.3 billion on record $14.6 billion of revenue, which beat expectations from Wall Street.
Microprocessors are Costa Rica’s primary export according to their Foreign Trade Ministry. The country was building a name for itself as a tech center in Central America. Intel just put a damper on those plans. The influential company is closing their microchip assembly and testing operations leaving 1,500 locals unemployed. Intel previously touted their contributions to their Central American host country. They indicated that the company participated in social responsibility projects in the community, focusing on education and the environment. Earlier, Intel proudly proclaimed: “While Costa Rica has historically been known for exporting coffee beans and bananas, thanks to Intel’s investment there, those traditional exports